Abstract: Oligonucleotide analogue arrays attached to solid substrates and methods related to the use thereof are provided. The oligonucleotide analogues hybridize to nucleic acids with either higher or lower specificity than corresponding unmodified oligonucleotides. Target nucleic acids which comprise nucleotide analogues are bound to oligonucleotide and oligonucleotide analogue arrays.

Abstract: The present invention is related to a DNA comprising a nucleotide sequence encoding a polypeptide represented by SEQ ID NO:1 or SEQ ID NO:2. The DNA according to the present invention is highly expressed in prostatic adenocarcinoma and ovarian carcinoma, and is a cancer-associated gene, so that it is possible to inhibit cancer by blocking the binding of the present protein to its ligand. Accordingly, the present antibody is used not only in the detection of the present protein, but also as an agent for the treatment or prevention of cancers such as prostatic adenocarcinoma and ovarian carcinoma.

Abstract: An object of the present invention is to provide a fluorescent protein derived from organisms other than Aequorea victoria and having a novel primary structure. According to the present invention, there is provided a fluorescent protein derived from Halcurias sp. L, which has the following properties: (1) the excitation maximum wavelength is 494 nm, and the fluorescence maximum wavelength is 506 nm; (2) the molar absorption coefficient at 494 nm is 94600 M?1 cm?1; (3) the quantum yield is 0.65; and (4) the pH sensitivity of the fluorescent property is low in the range between pH 4 and pH 11.

Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.

Abstract: The present invention provides nucleic acid and polypeptide sequences describing a novel canine cold- and menthol-sensitive receptor, herein named as canine CMR1 (cCMR1). The isolated nucleic acid or polypeptide molecule of the invention can be used in detection assays and screening assays.

Abstract: A reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered. Further, fungal genes conferring resistance to the above compounds were identified and methods of screening for compounds that inhibit the activity of the proteins encoded by these genes were developed. These genes encode proteins participating in fungal cell wall synthesis. Therefore, through the novel compounds, the present invention showed that antifungal agents having a novel mechanism, i.e. inhibiting the process that transports GPI-anchored proteins to the cell wall, could be achieved.

Abstract: The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated fatty acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to ?3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, ?6-docosapentaenoic acid or ?3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: An isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence that is complementary to a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a vector comprising such an isolated or purified nucleic acid molecule; a cell comprising such a vector; an isolated or purified polypeptide molecule consisting essentially of an amino acid sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a cell line that produces a monoclonal antibody that is specific for an aforementioned isolated or purified polypeptide molecule; and the monoclonal antibody produced by the cell line; methods of diagnosing a cancer or a predisposition to a cancer in a male or female mammal; a method of prognosticating a cancer in a mammal; a method of assessing

Abstract: The present invention is directed to galanin receptor 2 (GAL-R2) proteins and nucleic acids.

Abstract: The abundance of the 96 most abundant EST cluster sequences in a wheat lemma/palea cDNA library was investigated in a range of cDNA libraries made from various wheat tissues. 30 cDNA sequences showing highly enhanced abundance in lemma, palea and glume tissues over leaf, stem, embryo, endosperm and root tissue were selected for further analysis. These wheat EST cluster sequences were used to identify rice cDNA homologs. The abundance of the rice cDNA homologs was compared in rice leaf and panicle (includes lemma and palea) cDNA libraries. Rice cDNAs showing preferential expression in the panicle were then used to identify homologous rice genomic DNA clones, the putative promoter sequences have been identified and cloned.

Abstract: The present invention relates to expression cassettes comprising transcription regulating sequences with seed-preferential or seed-specific expression profiles in plants obtainable from Arabidopsis thaliana genes At4g12910, At1g66250, At4g00820, At2g36640, At2g34200, At3g11180, At4g00360, At2g48030, At2g38590, At1g23000, At3g15510, At3g50870, At4g00220, or At4g26320.

Abstract: Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.

Abstract: The invention is a method for detecting and measuring T-cell receptor (TCR) repertoires from mammalian lymphocytes. The method is based on the use of the multiple sets of unique primers to amplify 22 regions of the TCR V? region and thereby detect clonal expansions related to antigen stimulation of the immune system. Kits containing sets of primers and specialized analytical statistical software for use in determining clonal expansion in humans and mice are disclosed. The reliability, efficiency and short assay time in using the method is well suited to monitoring immune response to vaccination and therapeutic treatments for immune disorders.

Abstract: Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B are provided. Also provided are methods of using these compounds to modulate the growth of cancer cells, including p53-deficient cancer cells.

Abstract: Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.

Abstract: A free-flowing, hydrophobic starch composition has a near-neutral dry product pH. Methods for making the hydrophobic starch composition by preparing an aqueous mixture comprising a starch, a siliconate, and an acid, where the aqueous mixture has a near-neutral pH, and drying the starch solids to obtain a hydrophobic starch. Novel fuel compositions comprise hydrophobic starch which can be used in internal combustion engines, such as diesel engines. Hydrophobic starch compositions may be used as fuels or fuel components. Novel methods of fueling and operating internal combustion engines use hydrophobic starch as fuel or fuel components.

Abstract: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or acylated poly(alkylene oxide) or to a hydroxy group of a link residue itself carrying a residue of such poly(alkylene oxide).

Abstract: A method of preparing metal mesoporphyrin compounds is described. A metal mesoporphyrin compound may be formed by forming a novel mesoporphyrin IX intermediate compound and then converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. The novel intermediate compound may be formed by a catalytic hydrogenation of hemin in acid and subsequent recovery.

Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.

Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection:

Abstract: The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.

Abstract: The present invention includes a method of making of azidoaminotriazole (5-azido-2H-[1,2,4]triazol-3-ylamine), nitrosoguanazine dimer (N3-[(1E)-3-(4,5-diamino-4H-1,2,4-triazol-3-yl)-1,2-dioxidotriaz-1-enyl]-4H-1,2,4-triazole-3,4,5-triamine), novel nitrosoguanazine salts, azidonitraminotriazole/salts and the making of azidonitraminotriazole and salts, and novel metal complexes of an azidonitramine (4,6-diazido-N-nitro-1,3,5-triazin-2-amine) and the making of these metal complexes of this azidonitramine. Azidoaminotriazole, nitrosoguanazine, and azidonitramine compounds, their intermediates, and their salts may generally relate to energetic compounds, while nitrosoguanazine compounds and their metal salts may also have commercial potential in biomedical and pharmaceutical applications.

Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

Abstract: The invention relates to a high pressure method for producing pure melamine by pyrolyzing urea in a vertical synthesis reactor. The synthesis reactor has three stages above one another: a) in the first stage, the smaller portion of the total amount of urea is introduced into the central tube of a first tank reactor forming a first melamine-containing reaction medium; b) in the second stage, the first melamine-containing reaction medium and the larger portion of the total amount of urea is introduced into the central tube of a second tank reactor forming a second melamine-containing reaction medium; c) in the third stage, the second melamine-containing reaction medium is introduced into a vertical tubular flow reactor forming a raw melamine melt that is processed to obtain pure melamine.

Abstract: The present invention provides an adenine modified solid, ordered, mesoporous, bifunctional, organo-inorganic silica-based catalyst, its method of preparation and also a process for the production of cyclic carbonates of the formula hereinbelow wherein R?H, CH2Cl, CH3, C4H9, C6H11, C6H5.

Abstract: 4-Cyanocoumarin derivatives which have a distinct sensitivity to visible light, distinct luminescent ability, and satisfactory applicability for photochemical polymerization, dye lasers, and organic electroluminescent elements. Since most of the derivatives have a fluorescent maximum wavelength of 600 to 650 nm, particularly, 610 to 630 nm, they are extremely useful as luminescent agents for organic EL elements which emit visible light in a red-color region, and can be quite useful as luminescent agents in organic EL elements and laser-active substances in dye lasers, as well as luminous bodies as lighting sources for lighting devices, and information displays for visually displaying information.

Abstract: The present invention relates to compounds of formula IA wherein R1, R2, R3, and n are as defined in the specification, and to pharmaceutically active acid addition salts thereof. The compounds of the invention are useful in the treatment of neurological and neuropsychiatric disorders.

Abstract: The invention relates to novel 1-pyridin-4-yl urea derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.

Abstract: Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

Abstract: The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2(C2-C6 alkyl); R0, R2 and R3 are each independently —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), —OSO2(C2-C6 alkyl) or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; X is —S— or —HC?CH—; G is —O—, —S—, —SO—, SO2, or —N(R5)—, wherein R5 is —H or C1-C4 alkyl; and Y is —O—, —S—, —NH—, —NMe-, or —CH2—, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation, and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.

Abstract: Migrastatin and a migrastatin analog can be produced by fermentation of Streptomyces platensis NRRL 18993 and used in pharmaceutical formulations to treat cancer and/or inhibit metastasis of cancer cells.

Abstract: The present invention relates to a novel compound of formula (IV) which is an intermediate that can be used for the preparation of pioglitazone. It also relates to a method of obtaining the novel compound (IV) starting from the natural product L-tyrosine, in which the amino group is protected in the form of aromatic imino group, and a method of obtaining pioglitazone from the said intermediate.

Abstract: Compounds of Formula I, their N-oxides and salts are disclosed wherein A is O or S; G is a 5- or 6-membered heteroaromatic ring or a 5- or 6-membered nonaromatic heterocyclic ring optionally including one or two ring members selected from C(?O), SO or S(O)2, each ring optionally substituted with one to four R2; each J is independently a phenyl ring, a 5- or 6-membered heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused carbobicyclic or heterobicyclic ring system, wherein each ring or ring system is optionally substituted with one to four R3; and R1, R2, R3, R4 and n are as defined in the disclosure. A composition comprising a compound of Formula I, and a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula I are also disclosed.

Abstract: The present invention provides a novel and improved process for the preparation of Zonisamide and the intermediates thereof.

Abstract: A metal catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to give triazoles. In many instances, the reaction sequence regiospecifically ligates azides and terminal acetylenes to give only 1,4-disubstituted [1,2,3]-triazoles.

Abstract: The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity.

Abstract: In the present invention, the methods of producing a fluorinated cyclic benzamidine derivative (A), or a salt thereof, comprise the step of reacting a specific novel compound with ammonia or imide. The methods of this invention for producing a morpholine-substituted phenacyl derivative (B), or a salt thereof, comprise reaction of a specific novel compound with morpholine, reaction of the product with a halogenating reagent, and deketalization of the product. The methods of this invention for a producing cyclic benzamidine derivative (C), or a salt thereof, comprise the step of coupling compound (A), or a salt thereof, with compound (B), or a salt thereof, in the presence of an ether or a hydrocarbon.

Abstract: Pyrrolizine compounds having the formula (I), or pharmaceutically-acceptable salts thereof, are effective in treating inflammatory or immune diseases, where A is a four- to seven-membered saturated ring, K is O or S, and R1, R2, R3 n, and M are defined in the specification.

Abstract: The present invention relates to a process for the preparation of a N-(N?-substituted glycyl)-2-cyanopyrrolidine comprising at least (a) reacting, in the presence of dimethylformamide, a compound of formula (V) ?wherein, independently of each other, X1 and X3 are halogen; X2 is halogen, OH, O—C(?O)—CH2X3, —O—SO2—(C1-8)alkyl or 13 O—SO2-(aryl), ?with L-prolinamide, followed by (b) reacting the resultant compound without isolation with a dehydration agent, optionally followed by (c) reacting, in the presence of a base, the resultant compound without isolation with an appropriate amine and (d) recovering the resultant compound in free form or in acid addition salt form.

Abstract: A method of separating ZE-nepetalactone and EZ-nepetalactone from catnip oil involving mixing catnip oil dissolved in at least one water immiscible, non-halogenated organic solvent with at least one inorganic base dissolved in water to form a biphasic mixture, stirring the biphasic mixture to hydrolyze ZE-nepetalactone to form ZE-nepetalic acid, separating the aqueous phase containing ZE-nepetalic acid from the organic phase containing EZ-nepetalactone in the biphasic mixture, and optionally acidifying the aqueous phase to about pH 4.5 and adding at least one water immiscible, non-halogenated organic solvent to azeotropically lactonize the ZE-nepetalic acid in the presence of a catalytic amount of p-toluene sulfonic acid to form ZE-nepetalactone.

Abstract: Provided is a preparation process of a diglyceride-rich fat or oil, which includes bringing a fat or oil containing diglycerides in an amount of 50 mass % or greater and having a transition metal content of 5 ppm or less into contact with steam while forming a thin film of the fat or oil. This process makes it possible to prepare a diglyceride-rich fat or oil having a reduced odor and good color efficiently.

Abstract: The invention relates to compounds of formula (I) provided in the form of racemic compounds, mixtures of diastereomers or essentially pure diastereomers, wherein R1 represents a hydrogen atom or C1-C4-alkyl, and at least one secondary phosphine depicts an unsubstituted or substituted cyclic phosphine group, or phosphonium salts thereof having one or two monovalent anions or a divalent anion.

Abstract: Selected nickel complexes of the anions of certain 2-aminotropones are olefin polymerization catalysts. Novel 2-aminotropones and their nickel complexes are also disclosed together with methods of making these 2-aminotropones.

Abstract: The present invention provides methods for preparation of metallic amino acid chelates that are electrically neutral and free of interfering ions, by reacting a metal carbonate and an acidic amino acid in an aqueous solution, and the uses of said metallic amino acid chelates. The metallic amino acid chelates can be added to a product such as medical supplies, foods, beverages, cosmetics, feeds, etc., with maintaining the stability of the product at a variety of temperature and pH ranges and also having no effect on the properties of the product, including taste and appearance.

Abstract: To present a reaction system that efficiently catalyzes an enantio selective asymmetric nucleophilic addition reaction of an ?-iminophosphonic acid ester. An optically active ?-amino-?-oxophosphonic acid derivative is produced through an asymmetric addition reaction of an ?-iminophosphonic acid ester and a nucleophilic agent (for example, a silyl enol ether).

Abstract: The present invention provides a compound of the following formula (I): wherein R1 is methyl or 4-aminobutyl, which may be acylated; X is phenyl or substituted phenyl; W is an esterified group removable by hydrogenolysis. Also disclosed is the preparation method and the application of formula (I) compound.

Abstract: The present invention relates to series of compounds with aqueous metal decontamination activity and their uses in removing metals from aqueous media. The compounds are esters of organic acids or alcohols with polyols that contain a sulfhydral group (—SH). The compounds release sulfhydral slowly into the water providing activity over extended periods of time and exhibit biodegradable characteristics. The compounds may be used to remediate aqueous media.

Abstract: A method for producing MMA-d8 which includes a step of exchanging D in hydroxyl group of methanol-d4 represented by the formula: CD3OD with H to prepare the methanol-d3 represented by the formula CD3OH and simultaneously recovering a deuterium-containing compound, and a step of reacting methanol-d3 with sulfuric acid salt of methacrylic acid amide represented by the formula CD2=(CD3)CO(NH2.H2SO4) to prepare MMA-d8 represented by the formula: CD2=(CD3)COOCD3.

Abstract: Compounds of formula (I): wherein R1 represents optionally substituted C4-12 alkyl, optionally substituted C2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR3 or N(OR8)COR9; R2 represents SO2R10 or SO2NR10R11; R3 represents OR6, NR6R7 or NR6OH; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 and R7 each independently represents H, C1-6 alkyl, or C1-6 alkyl substituted with one or more heteroaryl groups, or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R8 and R9 each independently represents H or C1-6 alkyl; R10 and R11 each independently represents H or C1-6 alkyl; and and physiolo